The Interdisciplinary Care Team in Movement Disorder Care: Jean Hubble, MD


The semi-retired neurologist and consultant with the PMD Alliance discussed the importance of the patient care team and having multiple specialists and disciplines included in that process. [WATCH TIME: 2 minutes]

WATCH TIME: 2 minutes

“APPs, certainly, are an important part of an effective healthcare team for individuals with movement disorders. In my own experience—I was in practice in a Parkinson center in academic practice for many years, but then I transitioned several years ago to industry. I was fortunate, those many years ago, to have an APP that was an essential part of the care that we were able to render our patients.”

As the treatment for complex neurologic disease has progressed toward personalized medicine, the importance of multidisciplinary, or interdisciplinary, care teams has never been greater. As more knowledge is gleaned about the processes underpinning these diseases and the bodily systems that they effect, the need for more nuanced care has become similarly more apparent.

For movement disorder specialists such as Jean Hubble, MD, semi-retired neurologist, and consultant, PMD Alliance, this is all too obvious. The care of patients with movement disorders such as Parkinson disease, which also includes neurodegenerative effects, is complex, and thus requires the specialty of more than a single physician. Additional stakeholders, such as advanced practice providers, rehabilitation specialists, social workers, and others have become essential parts of the care team in the last decade.

At the 2022 Advanced Therapeutics in Movement and Related Disorders (ATMRD) Congress in Washington, DC, June 17-19, Hubble sat down with the PMD Alliance to share her perspective on the importance of these care teams. She offered insight into their roles in her experience and spoke about their abilities to help manage patients, particularly those being treated with some of the more advanced and complex treatment modalities.

Click here for more coverage of ATMRD 2022.

Related Videos
Michael Levy, MD, PhD
Michael Kaplitt, MD, PhD
Michael Kaplitt, MD, PhD
video 4 - "Amyloid Cascade Hypothesis of Alzheimer’s Disease"
Video 3 - "Amyloid Precursor Protein and Amyloid Beta Species in Alzheimer’s Disease"
Svetlana Blitshteyn, MD, FAAN, director and founder of Dysautonomia Clinic
© 2024 MJH Life Sciences

All rights reserved.